Latest Breaking News On - Preclinical data - Page 1 : comparemela.com

Clinical Trials Commenced For Promising Acclaim-3 Reqorsa® Immunogene Therapy In Combination With Tecentriq® To Treat Small Cell Lung Cancer: Genprex,

Clinical Trials Commenced For Promising Acclaim-3 Reqorsa® Immunogene Therapy In Combination With Tecentriq® To Treat Small Cell Lung Cancer: Genprex,
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoThomas gallagherGenentech tecentriqMoreno toscanoJosea moreno toscanoRodney varnerMark bergerTop company officersGenprex incUnited states incCompany phaseAmerican association for cancer researchBaltimore convention centerRoche groupTherapy focused

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesFrankfurt am mainBaden wübergWolfgang fischerArtiva alloMary beth sandinAlexander fudukidisIoanna tsoukalaEuropean hematology associationUniversity of texas md anderson cancer centerInstitute for tumor biologyAnnounces acceptancePreclinical dataInnate cell engagerHind medyoufTumor biology

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBen zeskindGina nugentLaurence wattsThomasj schallDrug administrationExchange commissionImmuneering corporationImmuneering corporation nasdaqDevelopment rd expensesCompany phaseAmerican association for cancer researchReports first quarterProvides businessPositive topline results

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesUniversity of texasComunidad autonoma de catalunaDavid anguloMahmoud ghannoumIrina kofflerNathan wiederholdNational institute of allergyDepartment of healthGlobe newswire scynexis incUniversity hospitals cleveland medical centerEuropean society of clinical microbiologyNational institutes of healthExchange commissionHuman services

Qualigen Therapeutics Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. “We continue to see cancers developing resistance to current clinical agents that tar

United statesUniversity of louisvilleSan diegoGeoff clarkJohn trentMichael poirierMike saboJoe burlisonRob monsenHoward donningerRachel ferrilTariq arshadGeoffreyj clarkAmerican association for cancer researchQualigen therapeutics incPoster includes